Cyfra21-1、CA125测定、B超检查对卵巢癌诊断及监测价值比较  

Comparison of Cyfra21-1,CA125 and B-Ultrasonographic Examination as Diagnostic and Monitoring Methods in Ovarian Cancer

作　　者：王建英[1] 程建新[1] 王淑英[2] 霍桐树[1] 苏杏满[1] 

机构地区：[1]河北医科大学第四医院,050011 [2]邯郸钢铁总厂职工医院,056001

出　　处：《实用癌症杂志》2003年第5期519-521,共3页The Practical Journal of Cancer

基　　金：河北省科技攻关计划项目资助 (992 761 2 4 6D)

摘　　要：目的　评价细胞角蛋白 19片段抗原 2 1 1(Cyfra2 1 1)、CA 12 5测定和B超检查在卵巢癌诊断和监测中的价值。方法　对 2 3例卵巢良性病变及 2 5例卵巢癌患者进行血清Cyfra2 1 1、CA12 5免疫放射测定和B超检查 ,并进行比较。 结果　Cyfra2 1 1、CA12 5测定和B超检查鉴别卵巢良性病变和卵巢癌的敏感性分别为 84.0 % ,80 .0 % ,84.0 %。特异性分别为 10 0 .0 % ,78.5 % ,82 .6%。 3种方法联合应用 ,对卵巢癌总的阳性检出率为 10 0 .0 % ,对Ⅰ期卵巢癌检出率为 80 .0 % (4 / 5 )。对 18例卵巢癌患者动态观察结果显示 ,Cyfra2 1 1和CA 12 5水平与病情进展一致。 结论　联合应用Cyfra2 1 1、CA 12 5测定和B超检查对诊断卵巢癌具有重要价值 ,Cyfra2 1 1和CA 12Objective To evaluate the significance of the cytokeratin 19 fragment(Cyfra21-1),CA125 and B-ultrasonographic examination in diagnosing and monitoring ovarian cancer.Methods Serum levels of Cyfra21-1 and CA125 were detected using an immunoradiometric assay in 23 patients with ovarian benign disease and 25 patients with ovarian cancer.All the patients were also examined by B-ultrasonography.Results The sensitivity,specificity were 84.0% and 100.0% for Cyfra21-1,80.0% and 78.5% for CA125,84.0% and 82.6% for B-ultrasonographic examination.Combining the three methods,diagnostic positive rate was 100.0% for ovarian cancer,and 80.0%(4/5) for stage I.Dynamic observation on 18 ovarian cancer patients showed that the levels of Cyfra21-1 and CA125 were consistently changed with the development of the illness.Conclusion Combining the methods of Cyfra21-1,CA125 and B-ultrasonographic examination has important diagnostic value for ovarian cancer.Cyfra21-1 and CA125 can be used to diagnose relapsed ovarian cancer.

关 键 词：CYFRA21-1 CA125 测定 B超 卵巢癌 诊断 监测 

分 类 号：R737.31[医药卫生—肿瘤]